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Background: There is a need for novel targeted therapies for metastatic ovarian cancers.
Results: We reactivated the tumor suppressor Maspin in ovarian carcinoma cells by delivering tumor-specific nanoparticles
encapsulating a chemically modified ATF-mRNA.
Conclusion: LPR nanoparticles encapsulating the ATF mRNA inhibited ovarian cancer tumor growth in a mouse model.
Significance: We report the first non-viral delivery of an ATF in vivo and the discovery of novel anti-metastatic targets for
ovarian cancer.
Ovarian cancer is the leading cause of death among gynecol-
ogicalmalignancies. It is detected at late stageswhen the disease
is spread through the abdominal cavity in a condition known as
peritoneal carcinomatosis. Thus, there is an urgent need to
develop novel therapeutic interventions to target advanced
stages of ovarian cancer. Mammary serine protease inhibitor
(Maspin) represents an important metastasis suppressor ini-
tially identified in breast cancer. Herein we have generated a
sequence-specific zinc finger artificial transcription factor
(ATF) to up-regulate theMaspinpromoter in aggressive ovarian
cancer cell lines and to interrogate the therapeutic potential of
Maspin in ovarian cancer. We found that althoughMaspin was
expressed in some primary ovarian tumors, the promoter was
epigenetically silenced in cell lines derived from ascites. Trans-
duction of the ATF inMOVCAR 5009 cells derived from ascitic
cultures of a TgMISIIR-TAg mouse model of ovarian cancer
resulted in tumor cell growth inhibition, impaired cell invasion,
and severe disruption of actin cytoskeleton. Systemic delivery of
lipid-protamine-RNAnanoparticles encapsulating a chemically
modified ATF mRNA resulted in inhibition of ovarian cancer
cell growth in nude mice accompanied with Maspin re-expres-
sion in the treated tumors. Gene expression microarrays of
ATF-transduced cells revealed an exceptional specificity for the
Maspin promoter. These analyses identified novel targets co-
regulated with Maspin in human short-term cultures derived
from ascites, such as TSPAN12, that could mediate the anti-
metastatic phenotype of the ATF. Our work outlined the first
targeted, non-viral delivery of ATFs into tumors with potential
clinical applications for metastatic ovarian cancers.
Epithelial ovarian carcinoma (EOC)3 is the seventhmost fatal
cancer worldwide and the deadliest malignancy affecting the
female reproductive organs (1). Serous ovarian carcinoma
(SOC) is the most common form of EOC, comprising 30–70%
of the cases (2). SOC is predominantly associated with p53
mutations, and loss of BRCA1/2 may also predispose to the
development of the disease (3, 4). This form is mostly detected
at advanced stages, when disease is widely spread and metasta-
sized into the abdomen, in a condition known as peritoneal
carcinomatosis. Late diagnosis is explained by the absence of
alarming symptoms and the lack of effective screening meth-
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ods. The lethality of this condition is due not only to late diag-
nosis but also to transient response to available therapies. Thus,
despite achieving optimal de-bulking with surgery and obtain-
ing adequate response to adjuvant chemotherapy, the majority
of cases will recur, and patients finally die because of resistant
metastatic disease (5–7). Unfortunately, the discovery of bio-
markers of metastatic progression and the development of
more effective treatments for SOChas been impeded due to our
limited understanding of the etiology and progression of the
disease.
Genetically engineered mouse models (GEMMs) of epithe-
lial cancers represent powerful model systems as they recapit-
ulate the essential molecular hallmarks of disease development
and progression that occur in humans (8). One of those mod-
els, the C57BL/6 TgMISIIR-TAg transgenic mouse, develops
EOC with metastatic features. Mouse ovarian carcinoma
(MOVCAR) cell lines derived from metastatic lesions (ascites)
of TgMISIIR-TAg mice recapitulate essential features of SOC,
particularly the metastatic potential (9). These cells have the
advantage that they can be easily manipulated in vitro to eluci-
date novel biomarkers of metastatic disease and to establish
novel delivery systems for therapeutic intervention (9).
Our laboratory has previously described a therapeutic
approach to target tumor and metastasis suppressors in cancer
cells using arrays of engineered, sequence-specific C2H2 zinc
finger (ZF) domains (10). Each ZF is composed of a recognition
-helix that binds 3 bp of DNA with high selectivity (11). Six
zinc finger (6ZF) arrays read an 18-base pair (18-bp) sequence
that is potentially unique in the human genome and provide a
high degree of genomic specificity and selectivity (12). Engi-
neering binding specificity is achieved by grafting the -helical
domain of each ZF known to interact with the target DNA
triplet (13). We have constructed multimodular 6ZF proteins
referred as artificial transcription factors (ATFs), recognizing
sequences in targeted promoters with dissociation constants in
the picomolar range (10, 13–18). In an ATF, the 6ZF scaffold
can be linked to a variety of protein modules to promote tran-
scriptional activation (19–23), repression (24, 25), and more
recently, epigenetic editing (26).
We have recently described an ATF (ATF-126) targeting the
human mammary serine protease inhibitor (Maspin), a tumor
andmetastasis suppressor gene initially identified in breast cells
(27). Although most epithelial cells express high levels ofMas-
pin, the promoter is down-regulated by epigeneticmechanisms
in several cancers, such as breast (28, 29) and ovarian cancer
(30). EndogenousMaspin reactivation by ATF-126 was associ-
ated with decreased tumor growth by enhancement of apopto-
sis (10), cell invasion (10), and suppression of metastatic colo-
nization in breast (18) and lung (31) cancer cells. Although
most studies have been focused on breast, prostate, and lung
cancer, the functional role of Maspin as tumor and metastasis
suppressor in EOC has not been investigated. Both cytoplasmic
and nuclear Maspin expression has been reported in some pri-
mary ovarian tumors and cell lines, with nuclear expression
being a favorable prognosis factor in ovarian cancer patients
(32). Decreased nuclearMaspin expression has been associated
with tumor grade and disease progression, suggesting a role of
Maspin silencing in advanced stages of ovarian cancer, poten-
tially in metastatic disease (32–34).
In this manuscript we took advantage of ZF technology to
target the endogenous murineMaspin promoter in metastatic
MOVCAR cell lines to interrogate the functional role and ther-
apeutic potential ofMaspin in EOC. Delivery of engineered ZF
proteins has historically been a major limitation for transla-
tional applications, most notably in cancer models. This paper
reports the first non-viral delivery of ATF mRNA for future
therapeutic treatment of serous epithelial ovarian cancer of
advanced stage and potentially for metastatic disease. We also
describe a panel of novel targets co-regulated with Maspin,
which could be used as potential biomarkers for future diagno-
sis and treatment of metastatic ovarian cancer.
EXPERIMENTAL PROCEDURES
Construction of a Murine-specific ATF Recognizing the Mas-
pin Promoter (mATF)—The murine-specific mATF was
designed to recognize an 18-bp duplex 5-GAAGACCTGG-
GTGTGGTC-3 located at127 nucleotides upstream the first
ATG triplet (translation start site) in the murine Maspin pro-
moter (Fig. 1A). The specific ZF coding sequences were gener-
ated by overlapping PCR as previously described (10), and the
specific-helical sequences used for the PCR are shown in sup-
plemental Fig. S1. The 6ZF cassettewas cloned into the SfiI sites
of the retroviral vector pMX-ss-IRES-GFP (10) for endogenous
gene regulation studies.
Cell Lines—The T11 cell line was a generous gift from Dr.
C. M. Perou (Lineberger Comprehensive Cancer Center,
Chapel Hill, NC) (35). Cells derived from the TgMMTV-PyMT
were kindly provided by Dr. S. Earp (Lineberger Comprehen-
sive Cancer Center, Chapel Hill, NC). M6CCT and M6C1
breast cell lines from a C3(1)tag mammary mouse model were
provided by J. E. Green (NIH, Bethesda, MD) (36). WNT1–
3160, WNT1-WG4, BRCA-B1.15, and BRCA-A1.8 cell lines
were generously supplied by Dr. L. Varticovski (NIH, Bethesda,
MD) and were maintained under culture conditions as previ-
ously reported (37–39). MOVCAR 5447, 5612, and 5009 were
cultured as described (9).
Retroviral Transduction of mATF in Cancer Cell Lines—Ret-
roviral transduction in the packaging cell line 293TGagPol
(ATCCNumber CRL-11654) and infection of the host cell lines
was performed as described (17) using the retroviral vector
pMX-IRES-GFP and the envelope protein plasmid pMDG.1.
The cells were infected every 8–12 h for a total of 3 times and
collected or fixed 72 h after the first infection for further exper-
iments. The Retro-X Tet-On expression system (catalog num-
ber 632104 CloneTech, Mountain View, CA) was used to gen-
erate a MOVCAR 5009 stable cell expressing the human
Maspin cDNA (purchased from Origene, catalogue number
SC303231, Rockville, MD) as described (18). To induceMaspin
cDNAexpression, cellswere treated for 48 hwith doxycycline 100
ng/l and collected for further experiments. The 293TGagPol
cells were grown in DMEM (Sigma) supplemented with 10% of
fetal bovine serum (FBS) and antibiotic-antimycotic solution
(Sigma).
Designer Zinc Fingers in Epithelial Ovarian Cancer
29874 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 35 • AUGUST 24, 2012
Treatment of the MOVCAR 5009 Cell Line with Epigenetic
Inhibitors—The MOVCAR 5009 cell line was treated with the
5-aza-2dC DNA-methyltransferase inhibitor and two histone
deacetylase inhibitors, suberoylanilide hydroxamic acid and tri-
chostatin A. Cells were treated at saturating concentrations of
drugs, as determined empirically for the MOVCAR 5009 cell
line: 5 M 5-aza-2dC, 10 M suberoylanilide hydroxamic acid,
and 100 nM trichostatin A. All drugs were purchased from
Sigma. Cells were plated at a density of 3 105 cells in 100-mm
plates (Corning, NY) in DMEM media and treated with the
corresponding inhibitors during 48 h. Cells were collected, and
RNAwas extractedwith RNeasyKit (Qiagen) and processed for
quantitative real time-PCR (qRT-PCR).
qRT-PCR Assays—RNA from adherent cell cultures and
tumor samples were extracted with the RNeasy kit (Qiagen)
and reverse-transcribed to cDNA using the High Capacity
cDNA reverse transcription kit (Applied Biosystems, Carlsbad,
CA). TaqMan Fast Universal MasterMix (Applied Biosystems)
and 150 ng of cDNA were used in the PCR reactions. GAPDH
was used as an endogenous control. Primers used for qRT-PCR
studies are shown in supplemental Table S4. The 7500 Software
Version 2.0.5. (Applied Biosystems) was used to analyze the
data. qRT-PCR was performed in duplicate wells and in three
independent experiments. Statistical differences were deter-
mined by Student’s t test considering p  0.05 as significant (*),
p  0.01 as highly significant (**), and p  0.001 as extremely
significant (***).
WesternBlot—Total protein extractwas obtainedwith radio-
immune precipitation assay buffer (Sigma R0278). The detec-
tion was performed with the Amersham Biosciences ECL
detection system (GE Healthcare). A detailed list of the anti-
bodies used in this study, the corresponding suppliers, and the
experimental dilutions are shown in supplemental Table S5.
Chromatin Immunoprecipitation (ChIP)—ChIP assay to
detect the ATF/polymerase II binding to the murine Maspin
promoter was performed as described elsewhere (40, 41). Pro-
tein-DNA complexes were pulled down with A/G beads (Santa
Cruz, sc-2003, Santa Cruz, CA). The beads were washed three
times with low salt buffer, three times with high salt buffer, and
two times with Tris-EDTA buffer (40, 41). The beads were
eluted overnight at 65 °C in elution buffer (Tris-EDTA buffer,
1% SDS, and 2l of proteinase K). DNAwas isolated by phenol-
chloroform extraction. The immunoprecipitated DNA was
amplified by PCR using the following primers flanking the
mATF binding site in theMaspin promoter: 5-CTGGGTGT-
GGTCACAGGTGAGC-3 and 5-TCCCTTTGCTTACCTT-
GAGTTGC-3. The primers against the murine GAPDH pro-
moter were used as controls for the PCR amplifications: 5-
TACTCGCGGCTTTACGGG-3 and 5-TGGAACAGGGA-
GGAGCAGAGAGCA-3 (42). The PCR products were loaded
in an agarose gel, and the relative -fold enrichment was deter-
mined by densitometry (ImageJ,NCBI, Bethesda,MD) andnor-
malized to the input samples.
Immunofluorescence—Cells were seeded in fibronectin-
coated coverslips and fixed with 10% formalin-PBS solution at
room temperature for 10 min. Cells were permeabilized with
0.5% Triton X, PBS for 15 min at 4 °C, and 4% BSA, PBS was
added for overnight blocking at 4 °C. Fibronectin, formalin, and
Triton-X were purchased from Sigma. MOVCAR 5009 cells
were transduced with mATF, control, or Maspin cDNA and
stained for detection of mATF, Maspin, and actin (supplemen-
tal Table S5). For immunofluorescence detection of Maspin
and tetraspanin 12 (TSPAN12) on epithelial ovarian cancer
specimens, paraffin sections (obtained from the UNC Tissue
Procurement Core) were deparaffinized, blocked at room tem-
perature with 5% BSA/PBS for 2 h, and incubated with primary
antibody overnight at 4 °C. The slides were next washed with
0.03%Tween 20, 1% BSA, PBS and stained with secondary anti-
bodies at room temperature for 1 h. Details regarding the anti-
body sources and dilutions are specified in supplemental Table
S5.
Cell Viability Assay—Cell viability was determined by Cell-
Titer Glo assay (Promega, Madison, WI) as described by the
manufacturer. Twenty-four hours post-transduction, 1000
cells perwell were seeded in 96-well plates, and cell viabilitywas
followed every 24 h for a total of 4 days. Statistical differences
were determined by Student’s t test considering p  0.05 as
significant (*), p  0.01 as highly significant (**), and p  0.001
as extremely significant (***).
Soft Agar Assay—Cells were collected 72 h post-transduc-
tion. Colony formation was assessed using six-well plates
(Corning). Five thousand cells per well were seeded on the top
layer of 0.3% agar with a 0.6% agar base layer. Plates were incu-
bated for 20 days in a 37 °C incubator with 5% CO2. Colonies
were visualized and counted after a 2-h treatmentwith a 0.005%
crystal violet solution. Cells were seeded in triplicate, and the
experiment was repeated three times. Materials were pur-
chased from Sigma unless otherwise stated.
Tumorsphere Assay—Cells were collected 72 h post-trans-
duction and counted. 20,000 cells were seeded in triplicatewells
in 6-well plates (low attachment plates, Corning, NY) in spher-
oid media: HuMEC medium (Invitrogen) containing 20 ng/ml
human EGF (BD Biosciences), 1 g/ml hydrocortisone (Stem
Cell Technologies, Vancouver, Canada), insulin 5 g/ml
(Sigma), and 1 B27 (Invitrogen) (43). The plates were incu-
bated at 37 °C in 5% CO2, and tumorspheres were visualized
using a cell culture Leica microscope 10 days after seeding.
Matrigel Invasion Assay—Matrigel Invasion Chambers (BD
Biosciences) were used to study cell invasion as previously
described (10). Briefly, cells were starved 24 h before the assay,
and 1  105 cells were seeded in the chambers. 24 h later cells
were fixed and stained with hematoxylin and eosin.
Preparation of Modified mRNA—The mATF coding se-
quence and enhanced green fluorescent protein (EGFP) were
cloned into pcDNA 3.1 vector flanked by an untranslated 5
strong Kozak translational initiation signal and a 3 -globin
sequence for higher translation efficiency and longer half-life.
The untranslated region and gene of interest was amplified by
PCR with 5 primer, CTAGAGAACCCACTGCTTACTGGC-
TTATCG, and 3 primer, 120TGCGTCGACACTAGTTCTA-
GACCCT. The amplicons were used as templates for in vitro
transcription. Modified mRNA was synthesized with Ambion
MEGAScript T7 kit (Invitrogen). A mix of 1.6 g of purified
amplicons, 6 mM 3-0-Me-m7G(5)ppp(5)G (New England
BioLabs, Ipswitch, MA), 1.5 mM guanosine triphosphate, 7.5
mM adenosine triphosphate, 7.5 mM 5-methylcytidine triphos-
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phate, 7.5 mM pseudouridine triphosphate, and 4 l of T7
enzyme were incubated at 37 °C for 46 h. The mRNA was
purified with Ambion MEGAclear kit (Invitrogen).
Preparation of Liposome and Liposome Protamine RNA
(LPR)—DOTAP (Avanti Polar Lipids, Alabaster, AL) and cho-
lesterol (Sigma) (1:1 mol/mol) were dissolved in chloroform,
and the solvent was removed under reduced pressure. The lipid
film was hydrated overnight with distilled water to make the
final concentration of 10 mM DOTAP and cholesterol. The
liposome was sequentially extruded through 400-, 200-, 100-,
and 50-nm polycarbonate membranes (Whatman, Piscataway,
NJ) to form 80  100-nm unilamellar liposomes. The LPR core
was prepared by mixing 146 l of solution A (10 g of mRNA)
and 146 l of solution B (3 l of 2mg/ml protamine, 12 l of 10
mM DOTAP/cholesterol liposome, and 131 l of distilled
water). The resulting solution was incubated at room tempera-
ture for 10min. The pegylationwas performed by adding 4l of
DSPE-PEG2000 (Avanti Polar Lipids) (10 mg/ml) and 4 l of
DSPE-PEG2000-AA (10 mg/ml) to the LPR core and incubating
the mix at 50 °C for 15 min. The DSPE-PEG-AA was synthe-
sized as previously described (44).
In Vitro Transfection of Nanoparticles in MOVCAR 5009
Cells—Ninety-six well plates were seeded with 1 104 cells per
well. The cells were transfected with either LPR-AA-EGFP or
LPR-EGFP nanoparticles equivalent to 0.5 g of modified
mRNA encoding EGFP. Nanoparticles were added to each well
in the presence of Opti-MEM medium (Invitrogen) and incu-
bated at 37 °C in 5% CO2. Themediumwas replaced with com-
plete medium for 4 h post-transfection. The transfection effi-
ciency was determined using a BD FACS Canto Flow
Cytometer (BD Biosciences). MOVCAR 5009 cells were trans-
fected with either LPR-AA-mATF or LPR-AA-control. The
control refers to the mATF modified mRNA lacking the 5 cap
nucleotide, which inhibits translation. TheHA.11 antibodywas
applied to determine mATF expression by immunofluores-
cence 24 h after transfection (supplemental Table S5). Trans-
fected cells were processed by MTT cell proliferation assays 2
days post-transfection as described by the manufacturer’s
instructions (RocheApplied Science). The absorbancewas read
at 570 nm to determine cell survival.
Molecular Beacon Design and Transfection—The software
Beacon Designer (PREMIER Biosoft International, Palo Alto,
CA) was employed to design amolecular beacon (MB) probe to
hybridizewith themouseMaspinmRNA.TheMBoligonucleo-
tide sequence 5-(Texas Red)(C6 amino)-CGCGATCTGTTT-
CTGATTCAGGAAATTTCTTCATGATCGCG-(3BHQ-
2)-3 was synthesized by The Midland Certified Reagent Co.
(Midland, TX). LPR nanoparticles loaded with 0.2 g of MB
and 0.8 g of mATF-mRNA were added into 8-well Lab-Tek
Chamber Slides. Twenty-four hours post-transfection cells
were examined with fluorescence microscopy observation.
Tumor Reduction Study—4–7-Week-old athymic nude
mice (obtained fromUniversity of North Carolina animalmod-
els core facility) were inoculated with 1  107 MOVCAR 5009
cells in the flank. Mice received an intravenous injection (via
tail vein) of nanoparticles equivalent to 10 g of mATF-
mRNA/control as a palpable solid tumor was formed (on day 16).
Mice received an injection every other day for five times. The
tumor sizes were monitored as an indication of therapeutic
effect. Statistical analysis was undertaken using Prism 4.0
GraphPad Software. The tumors were removed and analyzed
for expression of the mATF andMaspin reactivation by West-
ern blot.
siRNATransfection—Cells previously transducedwith either
control or mATF were collected 72 h post-transduction for the
siRNA experiment. The murine Maspin siRNA and a nonspe-
cific control siRNA targeting luciferase were purchased from
Thermo Scientific (Walthman, MA). Transfection was per-
formed using the manufacturer’s instructions. Briefly, 1  105
cells were plated in 6-well plates, and DharmaFECT 4 was used
to transfect the siRNA with a final concentration of 50 nM.
Transfected cellswere collected 48hpost-transfection andpro-
cessed for qRT-PCR analysis of Maspin and Tspan12 expres-
sion. Data were normalized to control-transfected samples.
Ovarian Cancer Patient-derived Samples—The normal
ovary preparation SR06, ovarian primary tumors, and ascites
were obtained from the Universidad Católica de Chile with
approved Institutional Review Board protocols. These samples
were resuspended in Trizol (Invitrogen) and processed for
expression analyses. Human ascites (ASC13 to 17) were
obtained from University of North Carolina hospitals with
approved Institutional Review Board protocols. These cells
were grown in RPMI media with 5% FBS in adherent tissue
culture plates as described above. Tumor cells were passaged
three times in tissue culture dishes and processed for qRT-PCR
orWestern blot. The epithelial origin of these cells was verified
by Western blotting using anti- Pan-Cytokeratin antibodies
(supplemental Fig. S4). For the qRT-PCR experiments the sam-
ples were analyzed using the GAPDH gene. Two additional
endogenous controls recommended for ovarian tumor speci-
mens (the genes glucuronidase  (GUSB) and peptidylprolyl
isomerase A (PPIA) (45, 46)) were also used to validate the
quantifications.
Gene Expression Microarrays—Total RNA was purified from
control andmATF-transduced cells (three biological replicates) as
described (18). ThemRNAwas amplified, labeled, and hybridized
as previously described (47) using Agilent mouse 4  180 K oligo
microarrays (Agilent Technologies). All microarray data have
been deposited in theGene ExpressionOmnibus (GEO) data base
under the accession numbers: GSM891209, GSM891210,
GSM891211, GSM891212, GSM891213, and GSM891214. The
probes/genes were filtered by requiring the lowest normalized
intensity values to be10 in both samples and controls. The nor-
malized log2 ratios (Cy5 sample/Cy3 control) of probes mapping
to the same gene were averaged to generate independent expres-
sionestimates. Statistical analysis ofmicroarray for gene expres-
sion data were performed using Significance Analysis of
Microarray. Gene ontology (GO) analysis was performed using
EASE: the Expression Analysis Systematic Explorer (48).
RESULTS
mATFBinds theMurineMaspin Proximal Promoter andUp-
regulates Its Expression in a Panel of Cell Lines Derived from
GEMMs—To up-regulate the murine Maspin promoter, we
designed a mATF targeting an 18-bp duplex located 127
nucleotides upstream the translation start site (Fig. 1A). This
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specific site was chosen because an 18-bp site at the same relative
position in the human promoter was successfully targeted by an
artificial zinc finger factor, ATF-126 (10). Moreover, because the
targeted site was not fully conserved between the murine and the
human promoter, the 6ZF helices were re-engineered to regulate
the murine counterpart (supplemental Fig. S1).
To have an initial assessment of the potency of the mATF in
reactivatingMaspin, we took advantage of a panel of breast and
ovarian cell lines derived from several GEMMs (Fig. 1,B andC).
We delivered the mATF and an empty vector (control) using
the pMX-IRES-GFP retroviral vector system (17). The mATF
was able to significantly up-regulate Maspin in all the murine
cancer cell lines examined carrying lowor silencedMaspin.The
gene expression data were normalized to the parental MMTV-
PyMT breast cancer line carrying the highest expression of
Maspin (Fig. 1B). As expected, no significant differences in gene
expression were observed between the parental and control-
transduced cell lines. We found that although Maspin was
expressed in some breast cancer cell lines, the genewas silenced
in all the ovarian cell lines derived from the TgMISIIR-TAg
transgenic mouse. Because of their high invasive potential and
their reported phenotypic resemblance to high grade EOC, we
focused further experiments using theMOVCAR5009 cell line.
In this background the mATF increased Maspin mRNA
expression by more than 70,000-fold relative to the parental
line, empty vector control cells, or a control vector carrying no
ZFs (VP64-SS sample, Fig. 2A). This regulation required a spe-
cific DNA binding as the delivery of a scramble library of ZF
proteins linked to VP64 (67) resulted in a significant reduction
(more than 3 orders ofmagnitude) ofMaspin activation relative
to the mATF, indicating that the specific 6ZF domains used for
the construction of the protein provided sequence-selectivity
(Fig. 2A). Interestingly, the reactivation ofMaspin by the engi-
neered protein was clearly superior to the reactivation of the
endogenous gene observed when the parental cell line
MOVCAR 5009 was treated with epigenetic inhibitors, such as
the DNAmethyltransferase inhibitor 5-aza-2dC (activation of
2564.9-fold over vehicle-control cells) and the histone deacety-
lase inhibitor trichostatin A (72.96-fold activation over vehicle
control-treated cells). Unlike the humanMaspin promoter (5),
the murine counterpart was not significantly up-regulated
upon exposure to the histone deacetylase inhibitor suberoyla-
nilide hydroxamic acid. Nevertheless, the clear reactivation of
Maspin with the methyltransferase inhibitor 5-aza-2dC sug-
gested that Maspin was silenced by promoter methylation in
theMOVCAR 5009 cell line. Our results are in agreement with
previous mapping of methylated CpG islands by sodium bisul-
fate sequencing in human ovarian cell lines (30) and suggest
that the Maspin promoter in metastatic ovarian cell lines is
down-regulated by epigenetic mechanisms.
To demonstrate the binding of the mATF to its cognate
sequence in theMaspin promoter, ChIP assays were performed
in the MOVCAR 5009 cells (Fig. 2B). Chromatin from empty
vector (control) and mATF-transduced cells was isolated, son-
icated, and processed for immunoprecipitation assays using an
anti-HA antibody to detect the tag engineered at the C termi-
nus of the ZF construct (Fig. 2B). The ChIP products were
amplified using primers specific for the Maspin promoter
sequences flanking the mATF site, and the enrichment of the
PCR products was evaluated by densitometry. As shown in Fig.
2B, mATF-transduced samples, but not controls, yielded the
expectedMaspin-specific 135-bp amplicon, suggesting that the
mATF was physically bound to its cognate site in the Maspin
promoter. Furthermore, when the ChIP assay was performed
using an anti-RNA-polymerase II antibody, the immunopre-
cipitated DNA was enriched in the mATF samples relative to
FIGURE 1. The artificial transcription factor mATF reactivates Maspin
expression in breast and ovarian cell lines derived from GEMMs. A, shown
is a schematic representation of the multidomain structure of the mATF bind-
ing the Maspin promoter. The DNA binding domain, composed of six ZF
motifs, was designed to bind an 18-bp sequence in the murine Maspin prox-
imal promoter at 127 bp upstream the translation start site. The ZF proteins
were linked to the VP64 transactivator domain (1). The hemagglutinin (HA)
tag was engineered at the C terminus of the ZF construct (68). B, the mATF
up-regulates Maspin mRNA expression in breast and ovarian cancer cell lines
derived from GEMMs as assessed by qRT-PCR. The mATF and empty vector
(control) were retrovirally transduced in the corresponding cell lines. Relative
Maspin up-regulation in both transduced and parental cell lines are shown in
the plot. Data were normalized to the parental MMTV-PYMT cell line. Stu-
dent’s t test was used to analyze the differences in gene expression between
the parental and the transfected cells (*, p  0.05; **, p  0.01; ***, p  0.001).
C, shown is an immunoblot analysis of Maspin up-regulation in cell lines
derived from GEMMs transduced either with control or mATF. A densitomet-
ric analysis of the Western blot is shown. Data were normalized to the MMTV-
PyMT cell line. Transgenic mouse strains and cell lines are indicated, and
sources are described under “Experimental Procedures.”
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control. This result suggests that the mATF transduction was
increasing the RNA-polymerase II binding in the Maspin pro-
moter, resulting in an enhanced transcriptional activity, as con-
firmed by qRT-PCR and Western blot (Fig. 1, B and C).
The reactivation ofMaspin by mATF in the MOVCAR 5009
cell line was further confirmed by immunofluorescence (Fig.
2C). In mATF-transduced cells, Maspin was found localized in
the cytoplasm and in the nucleus of the tumor cells. When a
Maspin cDNA-expressing retrovirus was used to exogenously
express Maspin, only cytoplasmic Maspin was detected in the
cells. Themolecular basis of the differentialMaspin localization
observed between the mATF- and the cDNA-transduced cells
is not known. A molecular hallmark of the ATFs is their ability
FIGURE 2. The artificial transcription factor mATF binds the Maspin pro-
moter in the MOVCAR 5009 cell line and reactivates silenced Maspin.
A, retroviral delivery of mATF specifically reactivates Maspin, as assessed by
qRT-PCR. VP64-SS refers to cells transduced with a vector carrying the trans-
activator domain but lacking the 6ZFs; ZF-VP64 indicates a scramble library of
3ZF domains linked to VP64 (69); Control refers to empty vector (pMX-IRES-
GFP)-transduced cells. The parental cell line was treated with the epigenetic
inhibitors: 5-aza-2dC (5 M), suberoylanilide hydroxamic acid (10 M), and
trichostatin A (100 nM) at saturating maximum doses. Data were normalized
to the parental cell line. B, mATF physically binds its targeted site in the Mas-
pin promoter. A ChIP assay was performed on the MOVCAR 5009 cell line
retrovirally transfected with either control (empty vector) or mATF. -RNA-
polymerase II (RNAPII), IgG Control, and -HA antibodies were used to immu-
noprecipitate the DNA-protein complexes. -HA facilitated the immunopre-
cipitation of mATF. Densitometric analysis of the ChIP products loaded on
agarose gels after PCR was carried out using the ImageJ software (NCBI,
Bethesda, MD). Data were normalized to the signal of the input sample. Ab,
antibody. C, retroviral transduction of mATF in MOVCAR 5009 cells results in
reactivation of both cytoplasmic and nuclear Maspin. Immunofluorescence
detected the nucleus (Hoechst 2258), the mATF expression (-HA, red), and
Maspin (green) in MOVCAR 5009 cells transduced with mATF, a Maspin
cDNA-expressing retrovirus (18), and an empty retroviral vector or control.
FIGURE 3. mATF expression induces a decrease in tumor cell viability and
invasion and promotes cytoskeleton disruption in the MOVCAR 5009
cell line. A, retroviral delivery of mATF decreases cell viability over control-
transduced cells as determined by Cell Titer Glo assay. Student’s t test was
applied to analyze the difference in tumor cell survival between the control
and mATF cells, with p  0.001. Three different transductions were per-
formed, each one monitored in triplicate wells. B, mATF decreases anchorage-
independent growth of MOVCAR 5009 cells. Soft agar colony formation
assays were performed on control and mATF-transduced cells. The arrow in
the picture (left) points to a colony amplified on the left corner. Colony quan-
tification was performed 20 days after the seeding. Three independent exper-
iments were carried out, and Student’s t test was applied to analyze the data;
p  0.0054. C, mATF-transduced cells abolished tumor formation potential, as
evaluated by tumorsphere assay formation. Cells were retrovirally trans-
duced with either mATF or control and seeded in low-attachment culture
plates with spheroid media (43). After 10 days, representative pictures of the
experiment are shown outlining the abolishment of spheroid formation in
mATF transduced cells. (p  0.0002). D, mATF transduction in MOVCAR 5009
cells inhibits the invasion potential of the cells relative to control, as assessed
by Matrigel-invasion assays (10). A representative picture of the fixed cells
after 24 h of invasion is indicated. Three independent experiments were per-
formed, and Student’s t test was applied to analyze the data; p  0.0001.
E, immunofluorescence staining of actin (green) and Maspin (red) on mATF
and control-transduced cells is shown. To detect actin, Alexa 488-phalloidin
was applied, and anti-Maspin-Alexa 594 was used as the secondary antibody
for Maspin detection. Hoechst 33258 was used to stain the nuclei (blue).
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to activate the endogenous promoters (23), resulting in tran-
scription of the physiologically relevant mRNA variants in the
proper ratios, which represents a fundamental difference from
the exogenous delivery of cDNAs (18).
mATF Expression Decreases Tumor Cell Viability and Inhib-
its TumorCell Invasion inMOVCAR5009—Toassess the effect
of the mATF expression on the phenotype of MOVCAR 5009
cells, we first performed cell viability assays using a CellTiter
Glo assay (Fig. 3A). The mATF-transduced cells and empty
vector control were harvested 72 h post-transduction, and the
cell viability was monitored every 24 h for a total of 4 days. We
found that the ATF significantly decreased the tumor cell via-
bility over time relative to control (p  0.001). A significant
decrease in cell viability was also observed when mATF was
transduced in otherMOVCAR cell lines carrying silencedMas-
pin, such as MOVCAR 5447 and 5612 (supplemental Fig. S2).
Transduction of mATF also suppressed anchorage-indepen-
dent growth of MOVCAR 5009 cells in soft agar colony forma-
tion assays (Fig. 3B). Furthermore, mATF completely sup-
pressed the ability of MOVCAR 5009 cells to form
tumorspheres in non-adherent plates, demonstrating that the
engineered protein suppressed the tumorigenic properties of
the cells in vitro (Fig. 3C). In addition to tumor suppression,
Maspin re-expression in breast cancer cells has been associated
with decreased motility and invasion (10, 18, 49). Consistent
with this second function ofMaspin, we found that the mATF
strongly suppressed the ability of MOVCAR 5009 cells to
invade the Matrigel (Fig. 3D). Notably, the mATF-expressing
cells underwent severe changes in cell shape, outlined by a dis-
ruption and loss of actin filaments (Fig. 3E).
LPR Nanoparticles Encapsulating a Chemically Modified
mATF mRNA Are Efficiently Internalized into MOVCAR 5009
Cells in Vitro and in Tumor Allografts—We next investigated
whether themATF could be delivered in the tumor cells using a
non-viral method by delivering chemicallymodifiedmessenger
RNA, eliminating the possibility of undesired genomic integra-
tion due to viral vector or plasmidDNAdelivery.We generated
LPR nanoparticles encapsulating the mATF mRNA. LPRs are
liposome-based nanocarriers capable of delivering chemically
modified RNAs to the targeted tumor site with high efficiency
and specificity (Ref. 76; Fig. 4A). The chemical ligand anisamide
(AA) was grafted at distal end PEG polymer on the surface of
LPR particles to target the sigma receptors (SRs), which are
overexpressed in a large spectrum of human tumors and cell
lines (50). In our study we employed LPR-AA nanoparticle
technology to deliver themATF to theMOVCAR5009 cell line.
The expression of SR1 in MOVCAR 5009 cells was confirmed
by Western blotting (supplemental Fig. S3). To evaluate the
FIGURE 4. Targeted LPR-AA nanoparticles encapsulating modified mATF mRNA results in functional production of the mATF and regulation of Maspin
in the MOVCAR 5009 cell line. A, shown is a schematic illustration of the generation of LPR-AA nanoparticles. The LPR nanoparticle core was prepared mixing
modified mRNA (e.g. EGFP, mATF, or control, which is the mATF lacking the 5 cap and is unable to translate) plus protamine and liposome. The LPR core was
pegylated by adding either DSPE-PEG2000-AA (targeted nanoparticle) or DSPE-PEG2000 (non-targeted). B, MOVCAR 5009 cells were transfected with either
LPR-AA-EGFP (targeted) or LPR-EGFP (non-targeted) nanoparticles, and the fluorescence intensity (quantification of the total fluorescence intensity of EGFP
events) was measured by flow cytometry 24 h post-transfection by gating the percentage % of EGFP-positive cells. Cells treated with nanoparticle controls not
carrying EGFP and untreated cells were used to generate the negative gates. A representative 10 picture of the transfected cells with LPR-AA-EGFP (targeted)
or LPR-EGFP (non-targeted) nanoparticles is shown. C, shown is immunofluorescence detection of the mATF (-HA, green) in MOVCAR 5009 cells. Cells were
transfected with either LPR-AA-mATF or control (uncapped mATF mRNA). The cells were stained 24 h after transfection. D, real-time detection of Maspin in
MOVCAR 5009 cells using an anti-Maspin molecular beacon (MB) is shown. Targeted nanoparticles containing either a functional mATF or an inactive control
were also loaded with an anti-Maspin MB. Red fluorescence emission due to the hybridization of the Maspin transcript with the MB was detected 24 h
post-transfection.
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transfection efficiency of the LPR-AA formulation, we encap-
sulated anmRNA encoding EGFP, and the expression level and
percentage of EGFP cells were evaluated by flow cytometry.
As shown in Fig. 4B,MOVCAR5009 cells were transfectedwith
85% efficiency and, thus, with a yield comparable with retro-
viral or lentiviral vectors. In addition, the transfection efficiency
was ligand-dependent. AA-LPR resulted in a 3-fold transgene
expression reflected by fluorescence intensity and a 2-fold per-
cent of transfected cells comparedwith non-targeted LPR. This
implied that efficient gene delivery with high specificity was
achieved as a result of enhanced receptor mediated cellular
uptake.Next, we investigatedwhether the delivery of functional
LPR-AA nanoparticles encapsulating the mATF mRNA
resulted in efficient translation of the mATF and in nuclear
localization of the designer protein. The expression of mATF
was detected by immunohistochemistry using an anti-HA anti-
body to detect the C-terminal epitope tag of the protein. As
shown in Fig. 4C, the functional mATF, but not an inactive
control ATF mRNA without 5 cap structure, was detected in
punctate structures in the nucleus of the cells, demonstrating
effective translation. To investigate whether the mATF was
transcriptionally competent in the cells, we co-transfected
either the mATF mRNA or the uncapped ATF mRNA control,
with amolecular beacon designed to specifically hybridize with
MaspinmRNA. In the presence of untranslated controlmRNA,
no Maspin mRNA transcript was detected by the molecular
beacon in the cells. However, when active mATF mRNA was
included in the nanoparticle, an activation of endogenousMas-
pin mRNA was detected by the molecular beacon probe that
allowed the real-time imaging of Maspin mRNA transcripts
with a perinuclear localization (Fig. 4D). Overall, these studies
demonstrated the delivery of our designer ZF protein into
nanoparticles to target the ovarian cancer cells under study and
effective mATF translation leading ultimately to Maspin
re-expression.
At last, the ability of mATF-loaded nanoparticles to induce
phenotypical changes in the cell line was evaluated in vitro (Fig.
5A). We found that LPR-AA-mATF nanoparticles significantly
decreased survival of theMOVCAR5009 cells by40% relative
to control-loaded nanoparticles, as determined by a cell viabil-
ity MTT assay (Fig. 5A). To assess the efficiency of LPR-AA
nanoparticles to target MOVCAR 5009 cells in vivo, LPR-AA-
mATF and control nanoparticles were delivered via intrave-
nous injections into mice bearing MOVCAR 5009 subcutane-
ous allografts. Nanoparticle injections were performed via tail
vein every 2 days with a total of 5 treatments. 24 days post-
injection, a significant inhibition of tumor growth was detected
on LPR-AA-mATF-injected animals relative to control (p 
0.0220) or vehicle-treated animals (p  0.0253) (Fig. 5B).
Tumors samples were processed by Western blot to demon-
strate effective expression of the mATF in the tumors and con-
comitantMaspin regulation (Fig. 5C). In summary, these stud-
ies demonstrated that nanoparticle delivery of mATF mRNA
led to a significant therapeutic effect inhibiting tumor cell
growth of MOVCAR 5009 tumor allografts.
Genome-wide Changes in Gene Expression by mATFDelivery
inMOVCAR5009Cells—To address the specificity ofmATF in
the MOVCAR 5009 cells, we performed gene expression
microarrays using Agilent mouse 4  180 K oligo microarrays.
Cells were transduced in three independent biological repli-
cates with either an empty retroviral vector (control) or with a
mATF-expressing retrovirus. Significantly differentially
expressed targets were analyzed using a two-class, unpaired
SAM, with a false discovery rate 5%. Supplemental Tables S1
and S2 contain the list of genes significantly up-regulated (505
genes) and down-regulated (383 genes), respectively. A gene
ontology (GO) analysis of the gene sets revealed gene pathways
involved in nuclear signaling, signal transduction by small
GTPases, cell motility, and adhesion (supplemental Table S3).
FIGURE 5. Transfection of LPR-AA-mATF nanoparticles decreases the pro-
liferation of MOVCAR 5009 cells in vitro and inhibits tumor growth in
vivo. A, delivery of LPR-AA-mATF nanoparticles decreases survival of
MOVCAR 5009 cells relative to control-treated targeted nanoparticles. Cell
survival was determined by MTT cell proliferation assay on cells transfected
with either LPR-AA-mATF or control. Student’s t test was applied to analyze
the difference on survival between mATF and control-transfected cells; p 
0.0002. Data represent the averages and S.E. of three independent experi-
ments, each one done in triplicate wells. B, LPR-AA-mATF nanoparticles
inhibit the growth of MOVCAR 5009 cells in subcutaneous allografts in nude
mice. MOVCAR 5009 cells were inoculated in nude mice to induce subcuta-
neous tumors, and nanoparticles were injected intravenously at the time
points indicated in the graph (arrows). Student’s t test was applied to analyze
the difference between control (n  9) and mATF treatment (n  9; p 
0.0220) and between vehicle and mATF (p  0.0253). C, mATF and Maspin
expression were detected on the treated tumors by Western blot. An anti-HA
antibody was used to detect the ATF by Western blot.
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Notably, the gene expressionmicroarray datasets revealed only
3 genes, includingMaspin, with a relativemRNAup-regulation
of 30-fold or higher over empty vector control (Table 1). These
findings were validated by qRT-PCR, as indicated in Fig. 6A.
The strongest mATF up-regulated target was Maspin, outlin-
ing the high degree of potency and specificity of the mATF in
MOVCAR 5009 cells. The genes Tetraspanin12 (Tspan12), cal-
cium and integrin binding family member 2 (Cib2), potassium
channel tetramerization domain containing 12 (Kctd12), and
potassium large conductance calcium-activated channel, sub-
family M,  member 4 (Kcnmb4) were also found up-regulated
inmATF-transduced samples relative to control-transduced or
parental line (p  0.0001). As shown in Table 1, the genes up-
regulated by mATF are membrane-associated proteins
involved in signal transduction, cell adhesion and migration,
and tumor suppression. The down-regulated targets (	0.13-
fold relative to control) included potential oncogenes such as
Wingless-related MMTV integration site 10a (Wnt10a) and
CCAAT/enhancer binding protein  (Cebpd) and regulators of
cell adhesion, such as Nidogen1 (Nid1) (Fig. 6B). In summary,
the analysis also revealed important novel targets co-regulated
withMaspin, which couldmediate the anti-metastatic and anti-
tumorigenic phenotype of the ZF factor in EOC cell lines.
Whether these targets represent indeed bona fide direct targets
of the ATF or downstream genetic cascades ofMaspin is pres-
ently not known and will require future molecular analyses, for
example by zinc finger mapping in their promoter sites. How-
ever, these genome-wide data documented a high degree of
potency and selectivity of mATF for its cognateMaspin target
in MOVCAR 5009 cells.
Maspin and TSPAN12 Are Down-regulated in Short-term
Cultures Derived fromHuman Ascites—We focused on the tar-
get TSPAN12, a member of the tetraspanin family of cell-sur-
face proteins, some of which have been reported to mediate
metastasis suppressive functions in several cancer models (51).
We interrogated whether TSPAN12 was co-regulated with
Maspin in a panel of primary ovarian cancer tumors specimens
and cell lines andwhether the genewas silenced in ascites prep-
arations fromovarian cancer patients. These samples were ana-
lyzed for Maspin and TSPAN12 expression by qRT-PCR (Fig.
7A). Data were normalized to the SR06 sample, a normal total
ovary preparation. We found that Maspin was expressed in
some ovarian primary tumors specimens and ovarian cell lines
but was low or undetectable in most of the ascites samples.
TSPAN12mRNAexpression followed a similar pattern andwas
significantly lower in the vastmajority of the ascites analyzed as
comparedwith primary tumors and ovarian cancer cell lines. In
one case examined, fromwhich pair samples of tumor and asci-
tes were available, the primary tumor (UC064) had significantly
higherMaspin and TSPAN12mRNA expression than the asci-
tes derived from the same patient (ASCUC064). As shown in
Fig. 7D and supplemental Fig. S5, the expression of Maspin
and TSPAN12 in primary EOC tumors was confirmed by
immunofluorescence in epithelial ovarian cancer tissue
specimens, Maspin having a predominantly cytoplasmic dis-
tribution, whereas TSPAN12 was localized on the plasma
membrane. The down-regulation of Maspin and TSPAN12
in the short-term cultures from ascites fluids was also vali-
dated by Western blotting using the OVCAR-3 tumor cell
line as reference (Fig. 7B).
The above results suggest that Maspin and TSPAN12 are
down-regulated in metastatic cells, opening the possibility that
TSPAN12 could be a downstream target of Maspin in ovarian
cancer. Alternatively, TSPAN12 could be regulated as a result
of mATF-dependent gene cascades, for example, by direct
binding of the ATF or by indirect regulation of downstream
targets. To address whether the activation of TSPAN12 in
mATF-transduced cells was dependent on Maspin, we chal-
lengedMOVCAR5009 cells transducedwithmATFwith either
a Maspin-specific siRNA or a control siRNA. Changes in
TSPAN12 were assessed in the transfected cells by qRT-PCR.
As shown in Fig. 7C, the Maspin knockdown resulted in a sig-
nificant down-regulation of TSPAN12 in the MOVCAR 5009
cells, suggesting that Maspin could be controlling TSPAN12
activation in these cells. In addition, we were unable to find
putative binding sites of the mATF in the TSPAN12 promoter,
suggesting that TSPAN12 is not a direct target of the ATF.
Moreover, more analyses need to be done, for example, using
genome-wide ZF mapping to validate the exact number and
genomic location of all mATF-binding sites in the cancer cell
genome. In summary, the gene expression analyses demon-
strated that the ZF technology could be used for cancer inves-
TABLE 1
Genes differentially regulated by mATF in the MOVCAR 5009 cell line
Name Alias -Fold changea Function
Up-regulated genes
Tetraspanin12 TM4SF12 TSPAN12 42.17 Member of the tetraspanin family of cell-surface proteins
mediating signal transduction. (70)
Mammary serine protease inhibitor Maspin SERPINB5 31.56 Tumor and metastasis suppressor gene. (27)
Calcium and integrin binding family
member 2
CIB2 KIP2 30.79 A related family member, CIB1, regulates cell migration. (71)
Potassium large conductance calcium-
activated channel, subfamily M, 
member 4
KCNMB4 h4 29.07 Auxiliary  subunit on MaxiK channels, increases calcium
sensitivity. (72)
Potassium channel tetramerisation domain
containing 12
KCTD12 PFETIN 26.15 Positive prognostic biomarker in gastrointestinal tumors. (73)
Down-regulated genes
Nidogen1 NID1 Enactin 0.0617 Suggested to play a role in cell interactions with the
extracellular matrix. (74)
CCAAT/enhancer-binding protein  CEBPD CELF 0.1266 Up-regulated in breast (75) and lung (76) cancers.
Wingless-related MMTV integration site
10a
WNT10A OODD 0.1171 Activator on the Wnt--catenin-TCF signaling pathway (77).
a Relative to control (empty vector).
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tigators to identify novel targets potentially involved in migra-
tion and metastatic progression for future diagnosis and
treatment of aggressive metastatic disease.
DISCUSSION
Mammary serine protease inhibitor (Maspin) has emerged as
an important clinical target possessing tumor and metastasis
suppressive functions. Although the function of Maspin has
been well examined in breast (52), lung (53), and prostate (54)
models, its function as a tumor and metastasis suppressor in
ovarian cancer has not been well investigated. In this paper we
took advantage of ZF technology to interrogate the role ofMas-
pin in metastatic ovarian cancer. We have described an mATF
able to up-regulate endogenous Maspin in metastatic murine
ovarian cancer cell lines derived from a TgMISRII-TAgGEMM
of serous ovarian cancer (9). The mATF had an exceptionally
strong transcriptional activation inmultiple murine cancer cell
models derived from GEMMs, with levels of expression that
were comparable with ectopic cDNA overexpression. The
higher transcriptional potency of the mATF relative to the pre-
viously reported human-specific ATF (ATF-126) could be
related to the configuration of the chromatin and the promoter
context of the mouse promoter. Moreover, MOVCAR 5009
cells derived from ascitic fluids from the C57BL/6 TgMISRII-
TAg GEMM exhibited an epigenetically silenced Maspin,
which could be partially re-activated by DNA methyltrans-
ferase (DNMT) and histone deacetylase inhibitors. In this back-
ground the mATF was able to bind its target site in the cell and
reactivated Maspin mRNA expression by more than 70,000-
fold relative to control-transduced and parental cells. The
much higher potency of the ATF in activating Maspin relative
to chromatin remodelers could be explained by the fact that the
ZFs confer locus selectivity. In contrast, epigenetic inhibitors,
such as DNAmethyltransferase (DNMT) and histone deacety-
lase inhibitors, are believed to target a large spectrum of tumor
suppressors. In addition, theMaspin-specific ZFs are linked to
the VP64 transactivator domain, which enhances transcription
by recruitment of several components of the transcription
machinery (55). Consistently, our ChIP analysis demonstrated
an enrichment of RNA-polymerase II binding in the Maspin
promoter uponmATF overexpression. Interestingly, the trans-
duction of mATF elevated both cytoplasmic and nuclear forms
of Maspin, whereas the exogenous cDNA overexpression up-
regulated only cytosolic Maspin. Recent publications outline
the importance of nuclear Maspin as being a favorable progno-
sis factor in breast (56), lung (57), and ovarian carcinomas (33).
This result emphasizes the significance of the endogenous
mechanisms of regulation of targeted promoters, which results
in activation of the physiologically relevant isoform of the tar-
geted gene. The phenotypic outcomes of Maspin reactivation
in metastatic MOVCAR 5009 cells recapitulated the effect of
the humanATF-126 in breast cancermodels (10, 18). Retroviral
delivery of mATF resulted in decreased cell viability, tumorige-
nicity, and strongly suppressed cell invasion. mATF induced
profound remodeling in the actin cytoskeleton, which could
have a negative impact in cell adhesion, migration, andmitosis.
mATF-transduction induced the formation of multiple focal
adhesions, indicating the cells were less prone to migration.
Our data are consistent with previous studies showing that
treatment with a recombinant Maspin protein, rMaspin,
resulted in increased adhesion and inhibition of cell invasion of
the breast carcinoma MDA-MB-435 cell line (58). rMaspin led
to changes in the cytoskeleton structure and increased the for-
mation of focal adhesions in metastatic breast cancer cells (59).
Our results with our designer protein confirm the role ofMas-
pin as metastasis suppressor in metastatic ovarian cancer by
modulating cell surface signaling pathways resulting in cyto-
skeleton remodeling.
To evaluate the specificity of the mATF in MOVCAR 5009
cells and to identify genesmediating the anti-tumor/metastatic
phenotype of the protein, we performed genome-wide gene
expression microarrays. These analyses revealed that only two
FIGURE 6. mRNA quantification of targets up- and down-regulated by
mATF in MOVCAR 5009 cells. Changes in mRNA expression of genes previ-
ously identified by gene expression microarrays (supplemental Table S1 and
Table S2) were validated by qRT-PCR. A, genes differentially up-regulated by
transduction of mATF in MOVCAR 5009 cells are shown. B, genes down-reg-
ulated by mATF are shown. Data were normalized to the parental MOVCAR
5009 cell line and represent the mean and S.D. of at least three independent
experiments. Differences in gene expression were calculated with a student t
test; ***, p  0.0001.
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targets were up-regulated together with Maspin, with a -fold
overexpression higher than 30 relative to control-transduced
cells. The subsequent qRT-PCR validation of these targets
demonstrated thatMaspinwas themost regulated target of the
ATF, outlining the high potency and specificity of the engi-
neered factor.
TSPAN12 belongs to the tetraspanin family of signal trans-
duction proteins, many of which act as tumor suppressors and
regulators of metastasis (51). Tetraspanins are transmembrane
proteins that physically associate with integrins to transduce
signals inside the cell (60). CD9 is a tetraspanin involved in
regulation of cell adhesion and motility (61). Down-regulation
FIGURE 7. Down-regulation of Maspin and TSPAN12 in short term human ascites preparations from ovarian carcinoma patients. A, expression of Maspin
and TSPAN12 in a panel of human ovarian primary tumors, ascites, and established cancer cell lines, as assessed by qRT-PCR is shown. Data were normalized to
SR06, a preparation of normal ovary. UC064 and ASCUC064 represent tumor sample and ascites preparation, respectively, from the same patient. Tumor
specimens, ascites preparations, and ovarian cell lines were homogenized and resuspended in Trizol for mRNA extraction and analyzed by quantitative
qRT-PCR. B, shown is an immunoblot of Maspin and TSPAN12 on protein extracts from human ascites, the human cell line OVCAR-3, and parental, control, and
mATF-transduced MOVCAR 5009 cells. C, down-regulation of Maspin and Tspan12 after Maspin siRNA knockdown in the mATF-transduced MOVCAR 5009 cell
line as assessed by qRT-PCR is shown. Data were normalized to the cell line transfected with a control (anti-luciferase) siRNA (*, p  0.05; **, p  0.01; ***, p 
0.001). D, shown is expression of Maspin and TSPAN12 by immunofluorescence in representative sections of epithelial ovarian cancer specimens (see also
supplemental Fig. S5).
Designer Zinc Fingers in Epithelial Ovarian Cancer
AUGUST 24, 2012 • VOLUME 287 • NUMBER 35 JOURNAL OF BIOLOGICAL CHEMISTRY 29883
of tetraspanin CD9 has been associated with metastatic behav-
ior and poor prognosis in lung (62), breast (63), and ovarian
cancers (64). CD9 down-regulates the expression of several
Wnt-associated proteins in lung adenocarcinoma and fibrosar-
coma cell lines (65). Interestingly, mATF delivery inMOVCAR
5009 cells led to an up-regulation of (TSPAN12) and a down-
regulation of Wnt10a suggesting that modulation of Wnt sig-
naling could be of therapeutic value for treatment of metastatic
ovarian cancer. Our results identified a novel target, TSPAN12,
thatwas founddown-regulated togetherwithMaspin in human
metastatic ovarian cancer cells derived from ascites. In sum-
mary, these results demonstrate that ZF could be used to poten-
tially discover novel molecular targets and regulators of metas-
tasis in ovarian cancer.
Delivery of ZF proteins has been an unbearable problem for
the transition of these agents into the clinic. In addition to effec-
tive delivery in pre-existing tumors, another fundamental prob-
lem is the specificity to the tumor tissue. To deliver the mATF
in MOVCAR 5009 tumor allografts, we developed LPR-AA
nanoparticles. The anisamide (AA) ligand coated at the surface
of the particles provides specificity for the sigma receptor (SR1)
(44), which is expressed at high levels in a vast spectrum of
cancer cell lines (50), including theMOVCAR 5009 cells. These
nanoparticles were designedwith a condensed core comprising
protamine and a chemicallymodifiedmATFmRNA.The deliv-
ery of modifiedmRNA circumvents limitations associated with
traditional plasmid DNA, such as nuclear delivery of DNA
through the nuclear envelope and host immunoresponse (76).
In vitro synthesis of chemically modified RNA using ribonucle-
otide analogues has been shown to suppress the innate immune
response by stimulating toll-like receptor and concomitantly
extend the half-life of the mRNAmolecule (66). Previous work
has demonstrated that chemically modifiedmRNA can be used
for delivery of reprogramming transcription factors for induc-
ible pluripotent stem cells in vitro (66). Indeed, we have found
that our LPR-AA nanoparticles transfected MOVCAR 5009
cells with efficiencies similar to retroviral delivery (60%). In
addition, the same LPR formulation was able to transfect some
breast cancer cell lines with efficiencies close to 100% (data not
shown) outlining the potential of the technology to effectively
deliver ZF proteins in tumor models. The LPR nanoparticles
were formulated such that high density of hydrophilic PEGwas
coated on the surface of the nanoparticles. The PEG coating
stabilized LPR in the presence of serum proteins and reduced
nonspecific uptake by reticuloendothelial system, extending
the half-life in the blood circulation after systemic administra-
tion. This led to the enhanced tumor accumulation due to the
enhanced permeability and retention. Notably, we demon-
strated that the LPR-mATF-AA nanoparticles resulted in
translation of ZF proteins in the tumor cells and in transactiva-
tion of the endogenous Maspin. When delivered intravenously
in aMOVCAR5009 allograftmodel, the LPR-mATF-AAnano-
particles significantly inhibited tumor growth, which was
accompanied by Maspin reactivation in the tumors. These
results are very encouraging and provide the first non-viral
delivery of ZF proteins in vivo for its potential use in clinical
trials to treat metastatic disease. Although our results demon-
strate proof-of-concept using nude mice, the next step will
require the intravenous injection of LPRs in a syngeneic or even
in the GEMM C57BL/6 TgMISRII-TAg of ovarian cancer,
which develops ovarian cancer in a similar progression as in
humans (9). In addition, future research will involve the intra-
peritoneal injection of LPRs inmice carrying abdominalmetas-
tases to assess the efficiency of the mATF to abolish pre-estab-
lished metastases. Given the explosion of publications using
both ZF and transcription activator-like effectors (TALEs)
technologies in the past decade (particularly in the domain of
gene therapy (67)), our results provide a novel non-viral deliv-
ery system of mRNA to be used for a broad spectrum of inves-
tigators working in the area of designer ZF factors.
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